Resultados de la búsqueda 861-870 of 17667 for dietary modifications

  1. Pérdida de peso LGBTQ health - Mayo Clinic

    The Mayo Clinic Diet. 3rd ed. Mayo Clinic Press; 2023. Interested in losing weight? Nutrition.gov. https://www.nutrition.gov/topics/healthy-living-and-weight/ ...

  2. Mayo Clinic Medical Professional Preferences

    Cancer. Quarterly eNewsletter that focuses on trends and advances in hematology and oncology at Mayo Clinic · Cardiovascular · Clinical Updates · Digestive ...

  3. Pérdida de peso Multimedia - Mayo Clinic

    The Mayo Clinic Diet. 3rd ed. Mayo Clinic Press; 2023. Interested in losing weight? Nutrition.gov. https://www.nutrition.gov/topics/healthy-living-and-weight/ ...

  4. Can you prevent cancer with lifestyle changes? ... Little by little: Small changes can lead to heart health, Mayo Clinic expert says Feb. ... 2020-2025 Dietary ...

  5. Oncología (médica) - Ensayos clínicos

    Diet may affect cytokine levels and inflammation (8). Diet rich in trans-fat and sugar has been shown to increase pro-inflammatory cytokines IL-6 and TNFα (9, ...

  6. Nefrología e hipertensión - Ensayos clínicos - Mayo Clinic

    The primary purpose of this study is to assess the feasibility of performing lung and kidney and lung ultrasound elastography among patients with critical ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Scottsdale/Phoenix, Ariz., Rochester, Minn. This phase II trial studies how well sapanisertib works in treating patients with pancreatic neuroendocrine tumor ...

  8. Pérdida de peso - Mayo Clinic

    The Mayo Clinic Diet. 3rd ed. Mayo Clinic Press; 2023. Interested in losing weight? Nutrition.gov. https://www.nutrition.gov/topics/healthy-living-and-weight/ ...

  9. Medicina Interna Hospitalaria - Ensayos clínicos - Mayo Clinic

    Infórmate más sobre los profesionales de atención médica que se ocupan de que los pacientes que están en un hospital de Mayo Clinic por una afección grave ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    In this study, participants with MSI-H or dMMR advanced colorectal carcinoma will be randomly assigned to receive either pembrolizumab or the Investigator's ...